Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.31 |
| ▸ | RRM1 | P23921 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067717 | 0.90 | RRM1 (0.34) | GHSRRRM1AKT1 | |
| SCHEMBL19575071 | 0.82 | SMN1; SMN2 (0.34) | AKT1 | |
| SCHEMBL16453450 | 0.81 | GLP1R (0.39) | CNR2ERAP2LNPEPGHSRERAP1 | |
| SCHEMBL26521168 | 0.80 | SMN1; SMN2 (0.36) | AKT1 | |
| SCHEMBL18494046 | 0.76 | LMNA (0.36) | AKT1 | |
| SCHEMBL22421821 | 0.75 | PTGS1 (0.39) | AKT1 | |
| SCHEMBL27270386 | 0.75 | SMN1; SMN2 (0.35) | AKT1 | |
| SCHEMBL19444592 | 0.74 | POLB (0.32) | AKT1 | |
| SCHEMBL25575447 | 0.74 | TSHR (0.36) | — | |
| SCHEMBL15096515 | 0.74 | CNR2 (0.45) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104353-A1 | LIGAND-TARGETED MOLECULES AND METHODS THEREOF | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104353-A1 | LIGAND-TARGETED MOLECULES AND METHODS THEREOF | HLCS, PAICS, CLTC | CNR2 2340/4885ERAP2 2426/4885LNPEP 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.